Compositions and methods relating to prevention of chemotherapy-induced alopecia
AssigneeHSF Pharmaceuticals SA
InventorRICHARD W. VOELLMY
Life of this patent
Estimating the term…
Loading patent…
AssigneeHSF Pharmaceuticals SA
InventorRICHARD W. VOELLMY
Estimating the term…
The present invention relates to a method for protecting a human patient or a mammalian animal to be subjected to chemotherapy treatment of a tumor not residing in the scalp of the patient or the skin of the animal against chemotherapy-induced alopecia, comprising administering to the scalp of the patient or the skin of the animal an effective amount of a composition comprising a chemical inducer of the stress protein response sufficiently prior to the administration of a chemotherapeutic drug. It also relates to pharmaceutical compositions for the prevention of chemotherapy-induced alopecia. It further relates to a method for protecting a human patient or a mammalian animal to be subjected to chemotherapy treatment of a tumor not residing in the scalp of the patient or the skin of the animal against chemotherapy-induced alopecia, comprising administering to the scalp of the patient or the skin of the animal an effective heat dose sufficiently prior to the administration of a chemotherapeutic drug.
A method of reducing chemotherapy-induced alopecia in a human patient or a mammalian animal to be subjected to chemotherapy treatment of a tumor not residing in the scalp or other region susceptible to chemotherapy-induced alopecia of the patient or the skin of the mammalian animal against chemotherapy-induced alopecia comprising:
A method for protecting a human patient or a mammalian animal to be subjected to chemotherapy treatment of a tumor not residing in the scalp of the patient or the skin of the animal against chemotherapy-induced alopecia, comprising administering to the scalp of the patient or the skin of the animal a composition comprising a chemical inducer of the stress protein response in an amount that is equal to or greater than that required to cause a detectable increase in the concentration of a stress protein selected from the group consisting of Hsp90, Hsp70, Hsp25-27 and P-glycoprotein in cells of hair follicles at the time of administration of a chemotherapeutic drug and subsequently administering a chemotherapeutic agent to said human patient or mammalian animal, wherein said chemical inducer of the stress protein response that is selected from the group consisting of diamide, a benzoquinone ansamycin, an arsenic salt, a tin salt, a zinc salt and an activated HSF1 in nucleic acid or protein form.
Dependencies are inferred from the claim text.